Source: SciTechDaily
“Researchers at Case Western Reserve School of Medicine have found that semaglutide, a popular drug used for both diabetes and weight loss, may reduce the risk of Alzheimer’s disease in people with type 2 diabetes (T2D) compared to seven other anti-diabetic medications. … Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a significantly lower risk of developing Alzheimer’s. This effect was observed consistently across various subgroups, including differences in obesity status, gender, and age.” (10/27/24)